Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupDermatologic OncologyDiseaseUveal MelanomaSubgroupHLA-A*02:01-positiveICD10C69.-MeSHUveal NeoplasmsSequenceTEBE(20/30/68), Uveal Melanoma, C1 (PID883) -|- TEBE68, C2+ (PID2080)ChemotherapyChemo-substanceGemcitabineHuman albumin 20%NaCl 0.9%TebentafuspTreosulfanChemo-substanceGemcitabineHuman albumin 20%NaCl 0.9%TebentafuspTreosulfanChemo-substanceGemcitabineHuman albumin 20%NaCl 0.9%TebentafuspTreosulfanChemo-substanceGemcitabineHuman albumin 20%NaCl 0.9%TebentafuspTreosulfanNo. Substances23 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneGranisetronSupportive substanceBalanced Crystalloid SolutionDexamethasoneGranisetronSupportive substanceBalanced Crystalloid SolutionDexamethasoneGranisetronSupportive substanceBalanced Crystalloid SolutionDexamethasoneGranisetronNo. Substances13Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationFirst lineseveral possibleTherapy phaseTherapy intentionpalliativeRisksDepigmentationEmetogenicity (MASCC/ESMO)Febrile NeutropeniaHyperbilirubinemiaHypertensionHypophosphatemiaHypotensionIncrease AminotransferasesLeukopeniaPruritusPyrexiaRashVomiting only studiesPublicationAuthorNathan PSchmittel ADiseasemetastasiertes Aderhautmelanom, HLA-A*02:01–positiv, Erstlinie, ECOG 0-1metastasiertes Adernhautmelanom, Karnofsky >60OriginDepartments of Internal Medicine III, Hematology, Oncology and Transfusion Medicine, Charité, GermanyMount Vernon Cancer Centre, UK, IMCgp100-202 InvestigatorsProtocols in Revision 3 protocols foundProtocols under revision.Gemcitabine 1000 / Treosulfan 3500, malignant Uveal Melanoma (PID1160 V1.0)Tebentafusp (20/30/68), Uveal Melanoma, Cycle 1 (PID883 V1.1)Tebentafusp 68, Uveal Melanoma, cycle 2+ (PID2080 V1.1)
